Event
BioTrinity 2026 | Meet our CEO & BD Team
Date: 14-15 April 2026
Location: London, UK
Ciriaco Maraschiello, CEO
Katie Headland, Senior Director
Business Development UK
Connecting Science and Business in Early Drug Discovery
Axxam will attend BioTrinity 2026, one of Europe’s leading partnering events focused on R&D, investment, and collaboration in the life sciences sector.
Our participation reflects Axxam’s commitment to building strategic partnerships that support innovation in early-stage drug discovery across pharma, biotech, and emerging companies.
What Axxam does
Axxam is a contract research organization (CRO) specialized in early-stage drug discovery, supporting partners through:
- Assay development for complex biological targets
- High-throughput and ultra-high-throughput screening
- Hit identification and hit-to-lead programs
- Integrated platforms combining biology, chemistry, and data
Our approach is designed to help partners make informed decisions and progress efficiently from target to candidate.
Meet Axxam at the Event
BioTrinity is a unique opportunity to explore collaborations, discuss scientific challenges, and identify new opportunities in drug discovery.